148P A phase II study of tislelizumab plus chemotherapy in EGFR mutated advanced non-squamous NSCLC patients failed to EGFR TKI therapies: First analysis

Abstract

throat and hypopharyngeal function retention rate was 84.6% (11/13). The pCR rate was 44.4% (12/27), and the major pathological response rate was 74.1% (20/27). The overall pathological downstaging rate was 100% (27/27). As of August 1, 2021, the median follow-up time was 10.5 months, and the median disease-free survival was not reached. Neoadjuvant therapy-related adverse events were all grade 1 or 2, except for a grade 3 rash reported in one patient. Regarding the surgical complications, 3 (11.1%) had intraoperative blood loss of >50 mL and 3 (11.1%) had pharyngeal leakage. No surgery-related bleeding or infection, or treatment-related death occurred.Conclusions: Neoadjuvant chemotherapy plus camrelizumab for locally advanced HNSCC showed extremely high ORR and pCR rate, and improved the rate of organ preservation, with an acceptable safety profile. This combination maybe a new treatment option for locally advanced HNSCC in the neoadjuvant setting.Clinical trial identification: This trial is registered with ChiCTR.org.cn, number ChiCTR1900025303, on August 22, 2019.

The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study

“…The median PFS and OS were 7.0 and 23.5 months, respectively, in that study, which were superior to historical data of traditional chemotherapy (21). Tislelizumab combined with chemotherapy has been reported to achieve an overall ORR of 59.4% and DCR of 90.6% in a phase II trial (22). Compared with the results of previous studies on single-agent ICIs, these data from prospective clinical trials suggest that combination therapy may significantly improve prognosis despite a lack of direct comparison.…”

“…With the further understanding of the synergistic mechanism of chemotherapy and immunotherapy, as well as the release of data from the clinical trial Impower150, more studies are focusing on the efficacy of immunotherapy-based combination treatment in EGFR-mutated NSCLC after EGFR-TKI resistance. In phase II trials, toripalimab and tislelizumab were reported to have objective response rates (ORRs) of 50.0% and 59.4% and disease control rates (DCRs) of 87.5% and 90.6%, respectively, in combination with chemotherapy as second-line treatment in pretreated EGFR-mutated advanced NSCLC (21,22). Several phase III trials are ongoing.…”

Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis

“…There are 23 clinical trials and 37 retrospective studies in patients with EGFR -mutant-positive NSCLC based on immunotherapy, and most data of them are from subgroups ( Tables 1 and 2 ) 9 , 11 , 17 – 74 . When pooling activity data in the meta-analysis indeed, the pooled ORR of EGFR -mutant patients treated with immunotherapy in clinical trials was 6% (95% CI: 3–9, I ² = 0%), while 8% (95% CI: 6–11, I ² = 43%) in retrospective studies ( Figure 2 ).…”

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis

“…Recent research has also investigated the efficiency of combinations of immunotherapy and chemotherapy. The ORR of toripalimab combined with carboplatin/pemetrexed in an intention-to-treat population was 54.8% ( Zhang et al, 2019 ), and that of tislelizumab combined with albumin paclitaxel/carboplatin was 59.4% ( Han et al, 2021 ). Immunotherapy combined with chemotherapy showed an advantage in terms of ORR in EGFR-mutant patients, but the final data remains to be investigated.…”